A. Prevotat

发表

Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study.

L. Meijer, S. Leroy, S. Hillion, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Infection pulmonaire à Mycobacterium abscessus chez une patiente diabétique traitée par l’association tigécycline-amikacine-céfoxitime

Y. Yazdanpanah, N. Veziris, É. Senneville, 2011 .

[Mycobacterium abscessus pulmonary infection treated with tigecyclin-amikacin and cefoxitin in a diabetic patient].

Y. Yazdanpanah, N. Veziris, É. Senneville, 2011, Medecine et maladies infectieuses.

Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease

A. Duhamel, B. Wallaert, C. Tardif, 2014, BMC Pulmonary Medicine.

An educational intervention about the classification of penicillin allergies: effect on the appropriate choice of antibiotic therapy in pregnant women.

K. Faure, D. Subtil, B. Grandbastien, 2020, International journal of obstetric anesthesia.

AGER -429T/C Is Associated with an Increased Lung Disease Severity in Cystic Fibrosis

P. Böelle, P. Reix, J. Dalphin, 2012, PloS one.

Virus and cystic fibrosis: Rhinoviruses are associated with exacerbations in adult patients

J. Salleron, I. Pin, L. Delhaes, 2014, Journal of Clinical Virology.

Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study

S. Leroy, A. Duhamel, G. Gargala, 2018, Mycopathologia.

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

P. Reix, P. Burgel, J. Paillasseur, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases

P. Reix, S. Rebuffat, E. Adriaenssens, 2017, PloS one.

[Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].

B. Wallaert, S. Leroy, T. Perez, 2010, Revue des maladies respiratoires.

Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis

M. Copin, B. Quesnel, M. Fertin, 2017, European Respiratory Journal.

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis

P. Berger, I. Pin, B. Wallaert, 2020, Scientific Reports.

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

C. Goss, H. Rodgers, P. Burgel, 2020, Journal of Cystic Fibrosis.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

D. Caimmi, A. Didier, S. Leroy, 2020, American journal of respiratory and critical care medicine.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

S. Leroy, P. Burgel, D. Grenet, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Computed tomographic airway morphology after targeted lung denervation treatment in COPD.

F. Herth, R. Eberhardt, J. Annema, 2022, Respiratory medicine.

Predictors of massive haemoptysis after a first episode of mild-to-moderate haemoptysis in patients with cystic fibrosis

B. Wallaert, O. Le Rouzic, T. Perez, 2020, ERJ Open Research.

First Wave of COVID-19 in French Patients with Cystic Fibrosis

P. Boelle, P. Burgel, L. Guillot, 2020, Journal of clinical medicine.

A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis

C. Goss, H. Rodgers, P. Burgel, 2020, Journal of Cystic Fibrosis.

The Airway Microbiota in Cystic Fibrosis: A Complex Fungal and Bacterial Community—Implications for Therapeutic Management

S. Leroy, J. Salleron, B. Wallaert, 2012, PloS one.

The 2,6-diaminopurine as a highly potent corrector of UGA nonsense mutations in cancers and other genetic diseases

E. Westhof, M. Copin, P. Reix, 2020 .

Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.

P. Burgel, J. Paillasseur, I. Durieu, 2021, American journal of respiratory and critical care medicine.

Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis.

P. Reix, M. Chamaillard, N. Prevarskaya, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy.

O. Le Rouzic, S. Gautier, S. Gilliot, 2022, The´rapie (Paris).

Fertility of women with cystic fibrosis: a French survey.

J. Parinaud, A. Fanton, C. Bettiol, 2019, Reproductive biomedicine online.

Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis

S. Leroy, B. Wallaert, O. Le Rouzic, 2019, ERJ Open Research.

Improvement in body composition following a supervised exercise-training program of adult patients with cystic fibrosis.

B. Wallaert, O. Le Rouzic, H. Bernard, 2019, Respiratory medicine and research.

Biphasic lung injury during Streptococcus pneumoniae infection in a murine model.

P. Gosset, K. Faure, B. Guery, 2017, Medecine et maladies infectieuses.

Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis

P. Berger, I. Pin, B. Wallaert, 2020, Scientific Reports.

Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis.

A. Clément, I. Sermet-Gaudelus, J. Derelle, 2017, Respiratory medicine.

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

C. Goss, H. Rodgers, P. Burgel, 2022, Journal of Cystic Fibrosis.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

S. Leroy, P. Burgel, D. Grenet, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].

T. Pérez, A. Prévotat, S. Leroy, 2010, Revue des maladies respiratoires.

Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection.

F. Batteux, E. Hachulla, R. Dessein, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.